Connection

Michael Gold to Middle Aged

Back to Details
This is a "connection" page, showing publications Michael Gold has written about Middle Aged.
Michael Gold
Connection Strength
3.077
Middle Aged
  1. The cost of non-response to cardiac resynchronization therapy: characterizing heart failure events following cardiac resynchronization therapy. Europace. 2021 10 09; 23(10):1586-1595.
    View in: PubMed
    Score: 0.054
  2. Impact of age on catheter ablation of premature ventricular contractions. J Cardiovasc Electrophysiol. 2021 04; 32(4):1077-1084.
    View in: PubMed
    Score: 0.052
  3. Predicting complete heart block after alcohol septal ablation for hypertrophic cardiomyopathy using a risk stratification model and clinical tool. Catheter Cardiovasc Interv. 2021 08 01; 98(2):393-400.
    View in: PubMed
    Score: 0.051
  4. Primary Results From the Understanding Outcomes With the S-ICD in Primary Prevention Patients With Low Ejection Fraction (UNTOUCHED) Trial. Circulation. 2021 01 05; 143(1):7-17.
    View in: PubMed
    Score: 0.050
  5. Relationship of Shock Energy to Impedance During Subcutaneous Implantable Cardioverter-Defibrillator Testing. Circ Arrhythm Electrophysiol. 2020 09; 13(9):e008631.
    View in: PubMed
    Score: 0.050
  6. Outcomes of subcutaneous implantable cardioverter-defibrillator in dialysis patients: Results from the S-ICD post-approval study. Heart Rhythm. 2020 09; 17(9):1566-1574.
    View in: PubMed
    Score: 0.049
  7. Electromagnetic interference from left ventricular assist devices in patients with subcutaneous implantable cardioverter-defibrillators. J Cardiovasc Electrophysiol. 2020 05; 31(5):1195-1201.
    View in: PubMed
    Score: 0.048
  8. The effect of posture, exercise, and atrial pacing on atrioventricular conduction in systolic heart failure. J Cardiovasc Electrophysiol. 2019 12; 30(12):2892-2899.
    View in: PubMed
    Score: 0.047
  9. Understanding Outcomes with the EMBLEM S-ICD in Primary Prevention Patients with Low EF Study (UNTOUCHED): Clinical characteristics and perioperative results. Heart Rhythm. 2019 11; 16(11):1636-1644.
    View in: PubMed
    Score: 0.046
  10. Effect of Interventricular Electrical Delay on Atrioventricular Optimization for Cardiac Resynchronization Therapy. Circ Arrhythm Electrophysiol. 2018 08; 11(8):e006055.
    View in: PubMed
    Score: 0.043
  11. Use of antibiotic envelopes to prevent cardiac implantable electronic device infections: A meta-analysis. J Cardiovasc Electrophysiol. 2018 04; 29(4):609-615.
    View in: PubMed
    Score: 0.042
  12. Impact of Renal Function on Survival After Cardiac Resynchronization Therapy. Am J Cardiol. 2017 Jul 15; 120(2):262-266.
    View in: PubMed
    Score: 0.040
  13. The Impact of the PR Interval in Patients?Receiving Cardiac Resynchronization Therapy: Results From the REVERSE Study. JACC Clin Electrophysiol. 2017 08; 3(8):818-826.
    View in: PubMed
    Score: 0.040
  14. The Design of the Understanding Outcomes with the S-ICD in Primary Prevention Patients with Low EF Study (UNTOUCHED). Pacing Clin Electrophysiol. 2017 Jan; 40(1):1-8.
    View in: PubMed
    Score: 0.039
  15. Economic Value and Cost-Effectiveness of?Cardiac Resynchronization Therapy Among Patients With Mild Heart Failure: Projections From the REVERSE Long-Term Follow-Up. JACC Heart Fail. 2017 03; 5(3):204-212.
    View in: PubMed
    Score: 0.039
  16. Utility of PET/CT to Evaluate Retroperitoneal Lymph Node Metastasis in High-Risk Endometrial Cancer: Results of ACRIN 6671/GOG 0233 Trial. Radiology. 2017 05; 283(2):450-459.
    View in: PubMed
    Score: 0.039
  17. Utility of PET-CT to evaluate retroperitoneal lymph node metastasis in advanced cervical cancer: Results of ACRIN6671/GOG0233 trial. Gynecol Oncol. 2016 Sep; 142(3):413-9.
    View in: PubMed
    Score: 0.038
  18. The Effect of Chronic Kidney Disease on Mortality with Cardiac Resynchronization Therapy. Pacing Clin Electrophysiol. 2016 Aug; 39(8):863-9.
    View in: PubMed
    Score: 0.037
  19. Impact of magnetic resonance imaging on ventricular tachyarrhythmia sensing: Results of the Evera MRI Study. Heart Rhythm. 2016 08; 13(8):1631-5.
    View in: PubMed
    Score: 0.037
  20. Vagus Nerve Stimulation for the Treatment of Heart Failure: The INOVATE-HF Trial. J Am Coll Cardiol. 2016 07 12; 68(2):149-58.
    View in: PubMed
    Score: 0.037
  21. Long-Term Extrapolation of Clinical Benefits Among Patients With Mild Heart Failure Receiving Cardiac Resynchronization Therapy: Analysis of the 5-Year Follow-Up From the REVERSE Study. JACC Heart Fail. 2015 Sep; 3(9):691-700.
    View in: PubMed
    Score: 0.035
  22. Full-Body MRI in Patients With an Implantable Cardioverter-Defibrillator: Primary Results of a Randomized Study. J Am Coll Cardiol. 2015 Jun 23; 65(24):2581-2588.
    View in: PubMed
    Score: 0.035
  23. The effect of reverse remodeling on long-term survival in mildly symptomatic patients with heart failure receiving cardiac resynchronization therapy: results of the REVERSE study. Heart Rhythm. 2015 Mar; 12(3):524-530.
    View in: PubMed
    Score: 0.033
  24. Use of a discrimination algorithm to reduce inappropriate shocks with a subcutaneous implantable cardioverter-defibrillator. Heart Rhythm. 2014 Aug; 11(8):1352-8.
    View in: PubMed
    Score: 0.032
  25. The effect of left ventricular electrical delay on the acute hemodynamic response with cardiac resynchronization therapy. J Cardiovasc Electrophysiol. 2014 Jun; 25(6):624-30.
    View in: PubMed
    Score: 0.032
  26. Implantable defibrillators improve survival in patients with mildly symptomatic heart failure receiving cardiac resynchronization therapy: analysis of the long-term follow-up of remodeling in systolic left ventricular dysfunction (REVERSE). Circ Arrhythm Electrophysiol. 2013 Dec; 6(6):1163-8.
    View in: PubMed
    Score: 0.031
  27. Plasma profiles of matrix metalloproteinases and tissue inhibitors of the metalloproteinases predict recurrence of atrial fibrillation following cardioversion. J Cardiovasc Transl Res. 2013 Aug; 6(4):528-35.
    View in: PubMed
    Score: 0.030
  28. Influence of intracardiac pressure on spontaneous ventricular arrhythmias in patients with systolic heart failure: insights from the REDUCEhf trial. Circ Arrhythm Electrophysiol. 2013 Apr; 6(2):272-8.
    View in: PubMed
    Score: 0.030
  29. Comparison of fixed tilt and tuned defibrillation waveforms: the PROMISE study. J Cardiovasc Electrophysiol. 2013 Mar; 24(3):323-7.
    View in: PubMed
    Score: 0.029
  30. Effect of QRS duration and morphology on cardiac resynchronization therapy outcomes in mild heart failure: results from the Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction (REVERSE) study. Circulation. 2012 Aug 14; 126(7):822-9.
    View in: PubMed
    Score: 0.028
  31. Interactions between a left ventricular assist device and implantable cardioverter-defibrillator. Pacing Clin Electrophysiol. 2012 Sep; 35(9):e272-3.
    View in: PubMed
    Score: 0.028
  32. Acute performance of a right ventricular automatic pacing threshold algorithm for implantable defibrillators. Pacing Clin Electrophysiol. 2012 Mar; 35(3):259-68.
    View in: PubMed
    Score: 0.027
  33. Head-to-head comparison of arrhythmia discrimination performance of subcutaneous and transvenous ICD arrhythmia detection algorithms: the START study. J Cardiovasc Electrophysiol. 2012 Apr; 23(4):359-66.
    View in: PubMed
    Score: 0.027
  34. Prospective comparison of discrimination algorithms to prevent inappropriate ICD therapy: primary results of the Rhythm ID Going Head to Head Trial. Heart Rhythm. 2012 Mar; 9(3):370-7.
    View in: PubMed
    Score: 0.027
  35. The relationship between ventricular electrical delay and left ventricular remodelling with cardiac resynchronization therapy. Eur Heart J. 2011 Oct; 32(20):2516-24.
    View in: PubMed
    Score: 0.027
  36. Modeling Alzheimer's disease progression using the disease system analysis approach. Alzheimers Dement. 2012 Jan; 8(1):39-50.
    View in: PubMed
    Score: 0.027
  37. A prospective, randomized comparison of the acute hemodynamic effects of biventricular and left ventricular pacing with cardiac resynchronization therapy. Heart Rhythm. 2011 May; 8(5):685-91.
    View in: PubMed
    Score: 0.026
  38. The impact of cardiac resynchronization therapy on the incidence of ventricular arrhythmias in mild heart failure. Heart Rhythm. 2011 May; 8(5):679-84.
    View in: PubMed
    Score: 0.026
  39. Defibrillation thresholds in hypertrophic cardiomyopathy. J Cardiovasc Electrophysiol. 2011 May; 22(5):569-72.
    View in: PubMed
    Score: 0.025
  40. Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study. Dement Geriatr Cogn Disord. 2010; 30(2):131-46.
    View in: PubMed
    Score: 0.025
  41. Randomized comparison of defibrillation thresholds from the right ventricular apex and outflow tract. Heart Rhythm. 2010 Nov; 7(11):1561-6.
    View in: PubMed
    Score: 0.025
  42. Acute hemodynamic effects of atrial pacing with cardiac resynchronization therapy. J Cardiovasc Electrophysiol. 2009 Aug; 20(8):894-900.
    View in: PubMed
    Score: 0.023
  43. Disparities in preferences for receiving support and education among patients with implantable cardioverter defibrillators. Pacing Clin Electrophysiol. 2009 Mar; 32(3):383-90.
    View in: PubMed
    Score: 0.022
  44. The effect of dofetilide on ventricular defibrillation thresholds. Pacing Clin Electrophysiol. 2009 Jan; 32(1):24-8.
    View in: PubMed
    Score: 0.022
  45. Implantable cardioverter-defibrillator therapy for primary prevention of sudden death after alcohol septal ablation of hypertrophic cardiomyopathy. J Am Coll Cardiol. 2008 Nov 18; 52(21):1718-23.
    View in: PubMed
    Score: 0.022
  46. Role of microvolt T-wave alternans in assessment of arrhythmia vulnerability among patients with heart failure and systolic dysfunction: primary results from the T-wave alternans sudden cardiac death in heart failure trial substudy. Circulation. 2008 Nov 11; 118(20):2022-8.
    View in: PubMed
    Score: 0.022
  47. Dynamic changes of T-wave alternans: does it predict short-term arrhythmia vulnerability? J Cardiovasc Electrophysiol. 2007 May; 18(5):518-9.
    View in: PubMed
    Score: 0.020
  48. Study design factors and patient demographics and their effect on the decline of placebo-treated subjects in randomized clinical trials in Alzheimer's disease. J Clin Psychiatry. 2007 Mar; 68(3):430-8.
    View in: PubMed
    Score: 0.020
  49. A prospective comparison of AV delay programming methods for hemodynamic optimization during cardiac resynchronization therapy. J Cardiovasc Electrophysiol. 2007 May; 18(5):490-6.
    View in: PubMed
    Score: 0.020
  50. Coronary sinus electrode does not reduce atrial defibrillation thresholds. Heart Rhythm. 2006 Jun; 3(6):647-52.
    View in: PubMed
    Score: 0.018
  51. Selective induction of matrix metalloproteinases and tissue inhibitor of metalloproteinases in atrial and ventricular myocardium in patients with atrial fibrillation. Am J Cardiol. 2006 Feb 15; 97(4):532-7.
    View in: PubMed
    Score: 0.018
  52. Sustained ventricular tachycardia following alcohol septal ablation for hypertrophic obstructive cardiomyopathy. Pacing Clin Electrophysiol. 2005 Dec; 28(12):1354-6.
    View in: PubMed
    Score: 0.018
  53. Comparison of stimulation sites within left ventricular veins on the acute hemodynamic effects of cardiac resynchronization therapy. Heart Rhythm. 2005 Apr; 2(4):376-81.
    View in: PubMed
    Score: 0.017
  54. Improved defibrillation efficacy with an ascending ramp waveform in humans. Heart Rhythm. 2005 Apr; 2(4):388-94.
    View in: PubMed
    Score: 0.017
  55. Clinical predictors of atrial defibrillation thresholds with a dual-coil, active pectoral lead system. Heart Rhythm. 2005 Jan; 2(1):49-54.
    View in: PubMed
    Score: 0.017
  56. Optimization of atrial defibrillation with a dual-coil, active pectoral lead system. J Cardiovasc Electrophysiol. 2004 Jul; 15(7):790-4.
    View in: PubMed
    Score: 0.016
  57. Electrocardiogram and clinical characteristics of patients referred for cardiac transplantation: implications for pacing in heart failure. Clin Cardiol. 2004 Mar; 27(3):151-3.
    View in: PubMed
    Score: 0.016
  58. Comparison of step-down and binary search algorithms for determination of defibrillation threshold in humans. Pacing Clin Electrophysiol. 2004 Feb; 27(2):218-20.
    View in: PubMed
    Score: 0.016
  59. Enhanced detection of arrhythmia vulnerability using T wave alternans, left ventricular ejection fraction, and programmed ventricular stimulation: a prospective study in subjects with chronic ischemic heart disease. J Cardiovasc Electrophysiol. 2004 Feb; 15(2):170-6.
    View in: PubMed
    Score: 0.016
  60. Effect of shock polarity on defibrillation thresholds with a hybrid patch-coil lead system. J Interv Card Electrophysiol. 2003 Dec; 9(3):391-6.
    View in: PubMed
    Score: 0.016
  61. Advanced rhythm discrimination for implantable cardioverter defibrillators using electrogram vector timing and correlation. J Cardiovasc Electrophysiol. 2002 Nov; 13(11):1092-7.
    View in: PubMed
    Score: 0.015
  62. Randomized Trial of Left Bundle Branch vs Biventricular Pacing for Cardiac Resynchronization Therapy. J Am Coll Cardiol. 2022 09 27; 80(13):1205-1216.
    View in: PubMed
    Score: 0.014
  63. Influence of QRS duration on the prognostic value of T wave alternans. J Cardiovasc Electrophysiol. 2002 Aug; 13(8):770-5.
    View in: PubMed
    Score: 0.014
  64. Clinical predictors of defibrillation thresholds with an active pectoral pulse generator lead system. Pacing Clin Electrophysiol. 2002 Apr; 25(4 Pt 1):408-13.
    View in: PubMed
    Score: 0.014
  65. Lack of benefit of an active pectoral pulse generator on atrial defibrillation thresholds. J Cardiovasc Electrophysiol. 2002 Apr; 13(4):332-5.
    View in: PubMed
    Score: 0.014
  66. Effects of selective autonomic blockade on T-wave alternans in humans. Circulation. 2002 Feb 19; 105(7):837-42.
    View in: PubMed
    Score: 0.014
  67. Comparison of the effects of active left and right pectoral pulse generators on defibrillation efficacy. Am J Cardiol. 2001 Dec 01; 88(11):1308-11.
    View in: PubMed
    Score: 0.014
  68. A new algorithm for transthoracic cardioversion of atrial fibrillation based on body weight. Am J Cardiol. 2001 Nov 01; 88(9):1043-5.
    View in: PubMed
    Score: 0.014
  69. Clinical experience with a dual-chamber implantable cardioverter defibrillator to treat atrial tachyarrhythmias. J Cardiovasc Electrophysiol. 2001 Nov; 12(11):1247-53.
    View in: PubMed
    Score: 0.014
  70. Efficacy and Safety of a Fixed-Dose Clindamycin Phosphate 1.2%, Benzoyl Peroxide 3.1%, and Adapalene 0.15% Gel for Moderate-to-Severe Acne: A Randomized Phase II Study of the First Triple-Combination Drug. Am J Clin Dermatol. 2022 Jan; 23(1):93-104.
    View in: PubMed
    Score: 0.014
  71. Contrast-enhanced image-guided lead deployment for left bundle branch pacing. Heart Rhythm. 2021 08; 18(8):1318-1325.
    View in: PubMed
    Score: 0.013
  72. Relationship of paced left bundle branch pacing morphology with anatomic location and physiological outcomes. Heart Rhythm. 2021 06; 18(6):946-953.
    View in: PubMed
    Score: 0.013
  73. Acute Hemodynamic Effects of Cardiac Resynchronization Therapy Versus Alternative Pacing Strategies in Patients With Left Ventricular Assist Devices. J Am Heart Assoc. 2021 03 16; 10(6):e018127.
    View in: PubMed
    Score: 0.013
  74. Using the years-of-healthy-life measure to calculate QALYs. Am J Prev Med. 2001 Jan; 20(1):35-9.
    View in: PubMed
    Score: 0.013
  75. Clinical predictors and efficacy of antitachycardia pacing in patients with implantable cardioverter defibrillators: the importance of the patient's sex. Pacing Clin Electrophysiol. 2001 Jan; 24(1):70-4.
    View in: PubMed
    Score: 0.013
  76. A comparison of T-wave alternans, signal averaged electrocardiography and programmed ventricular stimulation for arrhythmia risk stratification. J Am Coll Cardiol. 2000 Dec; 36(7):2247-53.
    View in: PubMed
    Score: 0.013
  77. Effect of second-phase duration on the strength-duration relation for human transvenous defibrillation. Circulation. 2000 Oct 31; 102(18):2239-42.
    View in: PubMed
    Score: 0.013
  78. IncobotulinumtoxinA Demonstrates Safety and Prolonged Duration of Effect in a Dose-Ranging Study for Glabellar Lines. J Drugs Dermatol. 2020 10 01; 19(10):985-991.
    View in: PubMed
    Score: 0.013
  79. Permanent His Bundle Pacing Implantation Facilitated by Visualization of the Tricuspid Valve Annulus. Circ Arrhythm Electrophysiol. 2020 10; 13(10):e008370.
    View in: PubMed
    Score: 0.013
  80. Bilateral Bundle Branch Area Pacing to Achieve Physiological Conduction System Activation. Circ Arrhythm Electrophysiol. 2020 08; 13(8):e008267.
    View in: PubMed
    Score: 0.012
  81. Acute hemodynamic effects of right ventricular pacing site and pacing mode in patients with congestive heart failure secondary to either ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol. 2000 May 01; 85(9):1106-9.
    View in: PubMed
    Score: 0.012
  82. Short term escape rhythm characteristics after radiofrequency ablation of the atrioventricular junction. J Interv Card Electrophysiol. 2000 Apr; 4(1):301-5.
    View in: PubMed
    Score: 0.012
  83. TMEM30A loss-of-function mutations drive lymphomagenesis and confer therapeutically exploitable vulnerability in B-cell lymphoma. Nat Med. 2020 04; 26(4):577-588.
    View in: PubMed
    Score: 0.012
  84. Signal-averaged isoharmonic body surface maps of patients with ischemic cardiomyopathy. J Cardiovasc Electrophysiol. 2000 Feb; 11(2):160-7.
    View in: PubMed
    Score: 0.012
  85. Sensing lead failure in implantable defibrillators: a comparison of two commonly used leads. J Cardiovasc Electrophysiol. 2000 Jan; 11(1):21-4.
    View in: PubMed
    Score: 0.012
  86. Optimization of transvenous coil position for active can defibrillation thresholds. J Cardiovasc Electrophysiol. 2000 Jan; 11(1):25-9.
    View in: PubMed
    Score: 0.012
  87. Real-world outcomes of ventricular tachycardia catheter ablation with versus without intracardiac echocardiography. J Cardiovasc Electrophysiol. 2020 02; 31(2):417-422.
    View in: PubMed
    Score: 0.012
  88. Evaluation, Management, and Outcomes of Patients Poorly Responsive to Cardiac?Resynchronization Device Therapy. J Am Coll Cardiol. 2019 11 26; 74(21):2588-2603.
    View in: PubMed
    Score: 0.012
  89. A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study. Ann Oncol. 2019 09 01; 30(9):1487-1495.
    View in: PubMed
    Score: 0.012
  90. Interaction of septadian and circadian rhythms in life-threatening ventricular arrhythmias in patients with implantable cardioverter-defibrillators. Am J Cardiol. 1999 Sep 01; 84(5):555-7.
    View in: PubMed
    Score: 0.012
  91. Cardiac arrhythmia: current therapy. Hosp Pract (1995). 1999 Sep 01; 34(9):27-8, 31-2, 35-8 passim.
    View in: PubMed
    Score: 0.012
  92. Atrial defibrillation with a transvenous lead: a randomized comparison of active can shocking pathways. J Am Coll Cardiol. 1999 Aug; 34(2):358-62.
    View in: PubMed
    Score: 0.012
  93. Comparison of bipolar and integrated sensing for redetection of ventricular fibrillation. Am Heart J. 1999 Jul; 138(1 Pt 1):133-6.
    View in: PubMed
    Score: 0.012
  94. Plasticity of left ventricular function with cardiac resynchronization therapy. J Interv Card Electrophysiol. 2020 Mar; 57(2):289-294.
    View in: PubMed
    Score: 0.011
  95. Left bundle branch pacing for symptomatic bradycardia: Implant success rate, safety, and pacing characteristics. Heart Rhythm. 2019 12; 16(12):1758-1765.
    View in: PubMed
    Score: 0.011
  96. Immediate and persistent complete heart block following a horse kick. Pacing Clin Electrophysiol. 1999 May; 22(5):816-8.
    View in: PubMed
    Score: 0.011
  97. The effect of procainamide on T wave alternans. J Cardiovasc Electrophysiol. 1999 May; 10(5):649-54.
    View in: PubMed
    Score: 0.011
  98. Intravenous amiodarone suppression of electrical storm refractory to chronic oral amiodarone. Pacing Clin Electrophysiol. 1999 Apr; 22(4 Pt 1):665-7.
    View in: PubMed
    Score: 0.011
  99. Factors Associated With High-Voltage Impedance and Subcutaneous Implantable Defibrillator Ventricular Fibrillation Conversion Success. Circ Arrhythm Electrophysiol. 2019 04; 12(4):e006665.
    View in: PubMed
    Score: 0.011
  100. Overdrive atrial pacing for conversion of atrial flutter: comparison of postoperative with nonpostoperative patients. Am Heart J. 1999 Jan; 137(1):100-3.
    View in: PubMed
    Score: 0.011
  101. The effect of shock configuration and delivered energy on defibrillation impedance. Pacing Clin Electrophysiol. 1999 Jan; 22(1 Pt 2):165-8.
    View in: PubMed
    Score: 0.011
  102. A new defibrillator discrimination algorithm utilizing electrogram morphology analysis. Pacing Clin Electrophysiol. 1999 Jan; 22(1 Pt 2):179-82.
    View in: PubMed
    Score: 0.011
  103. A comparison of pectoral and abdominal transvenous defibrillator implantation: analysis of costs and outcomes. J Interv Card Electrophysiol. 1998 Dec; 2(4):345-9.
    View in: PubMed
    Score: 0.011
  104. Inappropriate shocks from implanted cardioverter defibrillators caused by sensing of diaphragmatic myopotentials. J Interv Card Electrophysiol. 1998 Dec; 2(4):367-70.
    View in: PubMed
    Score: 0.011
  105. Competitive athletes with implantable cardioverter-defibrillators-How to program? Data from the Implantable Cardioverter-Defibrillator Sports Registry. Heart Rhythm. 2019 04; 16(4):581-587.
    View in: PubMed
    Score: 0.011
  106. Noninvasive tissue adhesive for cardiac implantable electronic device pocket closure: the TAPE pilot study. J Interv Card Electrophysiol. 2019 Mar; 54(2):171-176.
    View in: PubMed
    Score: 0.011
  107. The effect of delivered energy on defibrillation shock impedance. J Interv Card Electrophysiol. 1998 Sep; 2(3):273-7.
    View in: PubMed
    Score: 0.011
  108. Effect of heart rate on T wave alternans. J Cardiovasc Electrophysiol. 1998 Jul; 9(7):703-8.
    View in: PubMed
    Score: 0.011
  109. Toward consistency in cost-utility analyses: using national measures to create condition-specific values. Med Care. 1998 Jun; 36(6):778-92.
    View in: PubMed
    Score: 0.011
  110. Comparison of Hyaluronic Acid Gel With (HARDL) and Without Lidocaine (HAJUP) in the Treatment of Moderate-To-Severe Nasolabial Folds: A Randomized, Evaluator-Blinded Study. Dermatol Surg. 2018 06; 44(6):833-840.
    View in: PubMed
    Score: 0.011
  111. Comparison of single- and dual-coil active pectoral defibrillation lead systems. J Am Coll Cardiol. 1998 May; 31(6):1391-4.
    View in: PubMed
    Score: 0.011
  112. Effect of shock polarity on biphasic defibrillation thresholds using an active pectoral lead system. J Cardiovasc Electrophysiol. 1998 Apr; 9(4):350-4.
    View in: PubMed
    Score: 0.011
  113. Temporal stability of defibrillation thresholds with an active pectoral lead system. J Cardiovasc Electrophysiol. 1998 Mar; 9(3):240-4.
    View in: PubMed
    Score: 0.010
  114. Comparison of power- and temperature-guided radiofrequency modification of the atrioventricular node. Polaris Investigator Group. Am J Cardiol. 1997 Dec 01; 80(11):1444-7.
    View in: PubMed
    Score: 0.010
  115. Strength-duration relationship for human transvenous defibrillation. Circulation. 1997 Nov 18; 96(10):3517-20.
    View in: PubMed
    Score: 0.010
  116. Lead system optimization for transvenous defibrillation. Am J Cardiol. 1997 Nov 01; 80(9):1163-7.
    View in: PubMed
    Score: 0.010
  117. Effect of biphasic waveforms on transvenous defibrillation thresholds in patients with coronary artery disease. Am J Cardiol. 1997 Oct 15; 80(8):1098-100.
    View in: PubMed
    Score: 0.010
  118. Precision Medicine for Cardiac Resynchronization: Predicting Quality of Life Benefits for Individual Patients-An Analysis From 5 Clinical Trials. Circ Heart Fail. 2017 Oct; 10(10).
    View in: PubMed
    Score: 0.010
  119. Induction of atrial fibrillation with low-energy defibrillator shocks in patients with implantable cardioverter defibrillators. Am J Cardiol. 1997 Oct 01; 80(7):960-2.
    View in: PubMed
    Score: 0.010
  120. Subcutaneous Versus Transvenous Implantable Defibrillator Therapy: A Meta-Analysis of Case-Control Studies. JACC Clin Electrophysiol. 2017 12 26; 3(13):1475-1483.
    View in: PubMed
    Score: 0.010
  121. Comparison of class Ia/Ib versus class III antiarrhythmic drugs for the suppression of inducible sustained ventricular tachycardia associated with coronary artery disease. Am J Cardiol. 1997 Sep 01; 80(5):591-4.
    View in: PubMed
    Score: 0.010
  122. Permanent pacing from the coronary sinus in a patient with an implantable defibrillator. Pacing Clin Electrophysiol. 1997 Sep; 20(9 Pt 1):2286-7.
    View in: PubMed
    Score: 0.010
  123. Lidocaine-related increase in defibrillation threshold. Anesth Analg. 1997 Aug; 85(2):299-300.
    View in: PubMed
    Score: 0.010
  124. Biphasic waveforms prevent the chronic rise of defibrillation thresholds with a transvenous lead system. J Am Coll Cardiol. 1997 Jul; 30(1):233-6.
    View in: PubMed
    Score: 0.010
  125. Clinical predictors of transvenous biphasic defibrillation thresholds. Am J Cardiol. 1997 Jun 15; 79(12):1623-7.
    View in: PubMed
    Score: 0.010
  126. Distortion of intracardiac electrograms following defibrillator shocks for atrial tachyarrhythmias. Pacing Clin Electrophysiol. 1997 Jun; 20(6):1682-5.
    View in: PubMed
    Score: 0.010
  127. Effect of waveform tilt on defibrillation thresholds in humans. J Cardiovasc Electrophysiol. 1997 May; 8(5):496-501.
    View in: PubMed
    Score: 0.010
  128. The acute hemodynamic effects of right ventricular septal pacing in patients with congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol. 1997 Mar 01; 79(5):679-81.
    View in: PubMed
    Score: 0.010
  129. Left Ventricular Architecture, Long-Term Reverse Remodeling, and Clinical Outcome in Mild Heart Failure With Cardiac?Resynchronization: Results From the REVERSE Trial. JACC Heart Fail. 2017 03; 5(3):169-178.
    View in: PubMed
    Score: 0.010
  130. Chronic rise in monophasic defibrillation thresholds with a transvenous lead system. Am J Cardiol. 1997 Feb 15; 79(4):502-5.
    View in: PubMed
    Score: 0.010
  131. Clinical predictors of transvenous defibrillation energy requirements. Am J Cardiol. 1997 Jan 15; 79(2):150-3.
    View in: PubMed
    Score: 0.010
  132. Complications associated with pectoral implantation of cardioverter defibrillators. World-Wide Jewel Investigators. Pacing Clin Electrophysiol. 1997 Jan; 20(1 Pt 2):208-11.
    View in: PubMed
    Score: 0.010
  133. Performance of the subcutaneous implantable cardioverter-defibrillator in patients with a primary prevention indication with and without a reduced ejection fraction versus patients with a secondary prevention indication. Heart Rhythm. 2017 03; 14(3):367-375.
    View in: PubMed
    Score: 0.010
  134. Complications associated with pectoral cardioverter-defibrillator implantation: comparison of subcutaneous and submuscular approaches. Worldwide Jewel Investigators. J Am Coll Cardiol. 1996 Nov 01; 28(5):1278-82.
    View in: PubMed
    Score: 0.010
  135. Efficacy and safety of procainamide in preventing arrhythmias after coronary artery bypass surgery. Am J Cardiol. 1996 Nov 01; 78(9):975-9.
    View in: PubMed
    Score: 0.010
  136. Increased Monday incidence of life-threatening ventricular arrhythmias. Experience with a third-generation implantable defibrillator. Circulation. 1996 Sep 15; 94(6):1346-9.
    View in: PubMed
    Score: 0.009
  137. Effects of an active pectoral-pulse generator shell on defibrillation efficacy with a transvenous lead system. Am J Cardiol. 1996 Sep 01; 78(5):540-3.
    View in: PubMed
    Score: 0.009
  138. Chronic rise in defibrillation threshold with a hybrid lead system. Am J Cardiol. 1996 Aug 01; 78(3):309-12.
    View in: PubMed
    Score: 0.009
  139. Effects of waveform and polarity on defibrillation thresholds in humans using a transvenous lead system. Am J Cardiol. 1996 Aug 01; 78(3):313-6.
    View in: PubMed
    Score: 0.009
  140. Electrophysiologic effects and predictors of success of combination therapy with class Ia and Ib antiarrhythmic drugs for sustained ventricular arrhythmias. Am J Cardiol. 1996 Jul 01; 78(1):47-50.
    View in: PubMed
    Score: 0.009
  141. Image Quality of Cardiac Magnetic Resonance Imaging in Patients With an Implantable Cardioverter Defibrillator System Designed for the Magnetic Resonance Imaging Environment. Circ Cardiovasc Imaging. 2016 May; 9(5).
    View in: PubMed
    Score: 0.009
  142. Evaluation of subcutaneous ICD early performance in hypertrophic cardiomyopathy from the pooled EFFORTLESS and IDE cohorts. Heart Rhythm. 2016 05; 13(5):1066-1074.
    View in: PubMed
    Score: 0.009
  143. Effects of Cardiac Resynchronization Therapy on Cardiac Remodeling and Contractile Function: Results From Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction (REVERSE). J Am Heart Assoc. 2015 Sep 11; 4(9):e002054.
    View in: PubMed
    Score: 0.009
  144. Novel measure of electrical dyssynchrony predicts response in cardiac resynchronization therapy: Results from the SMART-AV Trial. Heart Rhythm. 2015 Dec; 12(12):2402-10.
    View in: PubMed
    Score: 0.009
  145. Acute electrophysiologic effects of amiodarone in patients with congestive heart failure. Am J Cardiol. 1995 Jun 01; 75(16):1158-61.
    View in: PubMed
    Score: 0.009
  146. Safety and Efficacy of the Totally Subcutaneous Implantable Defibrillator: 2-Year Results From a Pooled Analysis of the IDE?Study?and?EFFORTLESS Registry. J Am Coll Cardiol. 2015 Apr 28; 65(16):1605-1615.
    View in: PubMed
    Score: 0.009
  147. Rationale and Design of the Left Atrial Pressure Monitoring to Optimize Heart Failure Therapy Study (LAPTOP-HF). J Card Fail. 2015 Jun; 21(6):479-88.
    View in: PubMed
    Score: 0.009
  148. Spurious discharges due to late insulation break in endocardial sensing leads for cardioverter defibrillators. Pacing Clin Electrophysiol. 1995 Mar; 18(3 Pt 1):478-81.
    View in: PubMed
    Score: 0.009
  149. Overdrive pacing for atrial flutter. Am J Cardiol. 1994 Nov 15; 74(10):1021-3.
    View in: PubMed
    Score: 0.008
  150. Ischemically mediated sustained monomorphic ventricular tachycardia. Resolution with anti-ischemic therapy. Chest. 1993 Nov; 104(5):1613-4.
    View in: PubMed
    Score: 0.008
  151. Impact of ejection fraction on the clinical response to cardiac resynchronization therapy in mild heart failure. Circ Heart Fail. 2013 Nov; 6(6):1180-9.
    View in: PubMed
    Score: 0.008
  152. Safety and efficacy of a totally subcutaneous implantable-cardioverter defibrillator. Circulation. 2013 Aug 27; 128(9):944-53.
    View in: PubMed
    Score: 0.008
  153. Health insurance and mortality. Evidence from a national cohort. JAMA. 1993 Aug 11; 270(6):737-41.
    View in: PubMed
    Score: 0.008
  154. An individual patient meta-analysis of five randomized trials assessing the effects of cardiac resynchronization therapy on morbidity and mortality in patients with symptomatic heart failure. Eur Heart J. 2013 Dec; 34(46):3547-56.
    View in: PubMed
    Score: 0.008
  155. Long-term impact of cardiac resynchronization therapy in mild heart failure: 5-year results from the REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction (REVERSE) study. Eur Heart J. 2013 Sep; 34(33):2592-9.
    View in: PubMed
    Score: 0.008
  156. Multicenter, randomized, phase III study of a single dose of incobotulinumtoxinA, free from complexing proteins, in the treatment of glabellar frown lines. Dermatol Surg. 2013 Apr; 39(4):551-8.
    View in: PubMed
    Score: 0.007
  157. Chronic kidney disease and cardiac remodelling in patients with mild heart failure: results from the REsynchronization reVErses Remodeling in Systolic Left vEntricular Dysfunction (REVERSE) study. Eur J Heart Fail. 2012 Dec; 14(12):1420-8.
    View in: PubMed
    Score: 0.007
  158. Palliative care for patients with chronic obstructive pulmonary disease: exploring the landscape. Intern Med J. 2012 Sep; 42(9):1053-7.
    View in: PubMed
    Score: 0.007
  159. Sites of left and right ventricular lead implantation and response to cardiac resynchronization therapy observations from the REVERSE trial. Eur Heart J. 2012 Nov; 33(21):2662-71.
    View in: PubMed
    Score: 0.007
  160. Acute clinical evaluation of a left ventricular automatic threshold determination algorithm based on evoked response sensing. Pacing Clin Electrophysiol. 2012 Mar; 35(3):348-56.
    View in: PubMed
    Score: 0.007
  161. Esmolol and ventilatory function in cardiac patients with COPD. Chest. 1991 Nov; 100(5):1215-8.
    View in: PubMed
    Score: 0.007
  162. Reliability analysis of the resting state can sensitively and specifically identify the presence of Parkinson disease. Neuroimage. 2013 Jul 15; 75:249-261.
    View in: PubMed
    Score: 0.007
  163. Continuous hemodynamic monitoring in patients with mild to moderate heart failure: results of The Reducing Decompensation Events Utilizing Intracardiac Pressures in Patients With Chronic Heart Failure (REDUCEhf) trial. Congest Heart Fail. 2011 Sep-Oct; 17(5):248-54.
    View in: PubMed
    Score: 0.007
  164. Apathy, depression, and motor symptoms have distinct and separable resting activity patterns in idiopathic Parkinson disease. Neuroimage. 2013 Nov 01; 81:484-495.
    View in: PubMed
    Score: 0.007
  165. Effectiveness of Cardiac Resynchronization Therapy by QRS Morphology in the Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy (MADIT-CRT). Circulation. 2011 Mar 15; 123(10):1061-72.
    View in: PubMed
    Score: 0.006
  166. Cardiac resynchronization therapy in asymptomatic or mildly symptomatic heart failure patients in relation to etiology: results from the REVERSE (REsynchronization reVErses Remodeling in Systolic Left vEntricular Dysfunction) study. J Am Coll Cardiol. 2010 Nov 23; 56(22):1826-31.
    View in: PubMed
    Score: 0.006
  167. Primary results from the SmartDelay determined AV optimization: a comparison to other AV delay methods used in cardiac resynchronization therapy (SMART-AV) trial: a randomized trial comparing empirical, echocardiography-guided, and algorithmic atrioventricular delay programming in cardiac resynchronization therapy. Circulation. 2010 Dec 21; 122(25):2660-8.
    View in: PubMed
    Score: 0.006
  168. A multi-center randomized proof-of-concept clinical trial applying [?8F]FDG-PET for evaluation of metabolic therapy with rosiglitazone XR in mild to moderate Alzheimer's disease. J Alzheimers Dis. 2010; 22(4):1241-56.
    View in: PubMed
    Score: 0.006
  169. Cardiac resynchronization induces major structural and functional reverse remodeling in patients with New York Heart Association class I/II heart failure. Circulation. 2009 Nov 10; 120(19):1858-65.
    View in: PubMed
    Score: 0.006
  170. Prevention of disease progression by cardiac resynchronization therapy in patients with asymptomatic or mildly symptomatic left ventricular dysfunction: insights from the European cohort of the REVERSE (Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction) trial. J Am Coll Cardiol. 2009 Nov 10; 54(20):1837-46.
    View in: PubMed
    Score: 0.006
  171. Predictors of placebo response in pooled lamotrigine neuropathic pain clinical trials. Clin J Pain. 2009 Jul-Aug; 25(6):469-76.
    View in: PubMed
    Score: 0.006
  172. Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms. J Am Coll Cardiol. 2008 Dec 02; 52(23):1834-1843.
    View in: PubMed
    Score: 0.006
  173. Baseline characteristics of patients randomized in The Resynchronization Reverses Remodeling In Systolic Left Ventricular Dysfunction (REVERSE) study. Congest Heart Fail. 2008 Mar-Apr; 14(2):66-74.
    View in: PubMed
    Score: 0.005
  174. Limitations of ejection fraction for prediction of sudden death risk in patients with coronary artery disease: lessons from the MUSTT study. J Am Coll Cardiol. 2007 Sep 18; 50(12):1150-7.
    View in: PubMed
    Score: 0.005
  175. Serial evaluation of atrial tachyarrhythmia burden and frequency after implantation of a dual-chamber cardioverter-defibrillator. J Cardiovasc Electrophysiol. 2005 Jul; 16(7):708-13.
    View in: PubMed
    Score: 0.004
  176. Galantamine prolonged-release formulation in the treatment of mild to moderate Alzheimer's disease. Dement Geriatr Cogn Disord. 2005; 20(2-3):120-32.
    View in: PubMed
    Score: 0.004
  177. Efficacy of transthoracic cardioversion of atrial fibrillation using a biphasic, truncated exponential shock waveform at variable initial shock energies. Am J Cardiol. 2004 Dec 15; 94(12):1572-4.
    View in: PubMed
    Score: 0.004
  178. Timing isn't everything: an analysis of when to start salvage chemotherapy in ovarian cancer. Gynecol Oncol. 2004 Oct; 95(1):157-64.
    View in: PubMed
    Score: 0.004
  179. Seasonal variation of mortality in the Antiarrhythmics Versus Implantable Defibrillators (AVID) study registry. Heart Rhythm. 2004 Oct; 1(4):435-40.
    View in: PubMed
    Score: 0.004
  180. Termination of paroxysmal supraventricular tachycardia by tecadenoson (CVT-510), a novel A1-adenosine receptor agonist. J Am Coll Cardiol. 2003 Sep 17; 42(6):1098-102.
    View in: PubMed
    Score: 0.004
  181. A new pacemaker algorithm for the treatment of atrial fibrillation: results of the Atrial Dynamic Overdrive Pacing Trial (ADOPT). J Am Coll Cardiol. 2003 Aug 20; 42(4):627-33.
    View in: PubMed
    Score: 0.004
  182. Prevalence of sensing abnormalities in dual chamber implantable cardioverter defibrillators. Ann Noninvasive Electrocardiol. 2003 Jul; 8(3):219-26.
    View in: PubMed
    Score: 0.004
  183. Effect of an implantable cardioverter defibrillator with atrial detection and shock therapies on patient-perceived, health-related quality of life. Am Heart J. 2003 May; 145(5):841-6.
    View in: PubMed
    Score: 0.004
  184. Effect of implantable defibrillators on arrhythmic events and mortality in the multicenter unsustained tachycardia trial. Circulation. 2002 Jul 09; 106(2):233-8.
    View in: PubMed
    Score: 0.004
  185. National study of adverse reactions after vaccination with bacille Calmette-Gu?rin. Clin Infect Dis. 2002 Feb 15; 34(4):447-53.
    View in: PubMed
    Score: 0.003
  186. Analysis of FIGO Stage IIIc endometrial cancer patients. Gynecol Oncol. 2001 May; 81(2):273-8.
    View in: PubMed
    Score: 0.003
  187. Electrical storm presages nonsudden death: the antiarrhythmics versus implantable defibrillators (AVID) trial. Circulation. 2001 Apr 24; 103(16):2066-71.
    View in: PubMed
    Score: 0.003
  188. Lead- and device-related complications in the antiarrhythmics versus implantable defibrillators trial. Am Heart J. 2001 Jan; 141(1):92-8.
    View in: PubMed
    Score: 0.003
  189. Electrophysiologic testing to identify patients with coronary artery disease who are at risk for sudden death. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med. 2000 Jun 29; 342(26):1937-45.
    View in: PubMed
    Score: 0.003
  190. Alzheimers disease is not associated with the hypertension genetic risk factors PLA(2) or G protein beta3, either independently or interactively with apolipoprotein E. Am J Med Genet. 1999 Oct 15; 88(5):465-8.
    View in: PubMed
    Score: 0.003
  191. Comparison of the sedation and recovery profiles of Ro 48-6791, a new benzodiazepine, and midazolam in combination with meperidine for outpatient endoscopic procedures. Anesth Analg. 1999 Oct; 89(4):893-8.
    View in: PubMed
    Score: 0.003
  192. The alpha-2 macroglobulin gene is not associated with Alzheimer's disease in a case-control sample. Neurosci Lett. 1999 Aug 06; 270(3):133-6.
    View in: PubMed
    Score: 0.003
  193. Prediction of sustained ventricular tachycardia inducible by programmed stimulation in patients with coronary artery disease. Utility of clinical variables. Circulation. 1999 Apr 13; 99(14):1843-50.
    View in: PubMed
    Score: 0.003
  194. The -491A/T apolipoprotein E promoter polymorphism association with Alzheimer's disease: independent risk and linkage disequilibrium with the known APOE polymorphism. Neurosci Lett. 1998 Aug 14; 252(2):95-8.
    View in: PubMed
    Score: 0.003
  195. No association between the very low density lipoprotein receptor gene and late-onset Alzheimer's disease nor interaction with the apolipoprotein E gene in population-based and clinic samples. Genet Epidemiol. 1997; 14(3):299-305.
    View in: PubMed
    Score: 0.002
  196. Use of care and subsequent mortality: the importance of gender. Health Serv Res. 1996 Aug; 31(3):347-63.
    View in: PubMed
    Score: 0.002
  197. Prognostic importance of the length of ventricular tachycardia in patients with nonischemic congestive heart failure. Am Heart J. 1995 Sep; 130(3 Pt 1):489-93.
    View in: PubMed
    Score: 0.002
  198. Prognostic value of the signal-averaged electrocardiogram and a prolonged QRS in ischemic and nonischemic cardiomyopathy. Am J Cardiol. 1995 Mar 01; 75(7):460-4.
    View in: PubMed
    Score: 0.002
  199. Acute hemodynamic effects of atrio-biventricular pacing in humans. Ann Thorac Surg. 1995 Feb; 59(2):294-300.
    View in: PubMed
    Score: 0.002
  200. Racial differentials in the identification of hypercholesterolemia. J Fam Pract. 1993 Apr; 36(4):425-30.
    View in: PubMed
    Score: 0.002
  201. Electrophysiologic response to moricizine in patients with sustained ventricular arrhythmias. Ann Intern Med. 1992 Mar 01; 116(5):382-7.
    View in: PubMed
    Score: 0.002
  202. Hypomagnesemia is a frequent finding in the emergency department in patients with chest pain. Arch Intern Med. 1991 Nov; 151(11):2185-90.
    View in: PubMed
    Score: 0.002
  203. Barriers to cholesterol testing in a rural community. J Fam Pract. 1991 Jun; 32(6):614-8.
    View in: PubMed
    Score: 0.002
  204. Retroperitoneal cystic lymphangioma. AJR Am J Roentgenol. 1983 Apr; 140(4):733-4.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.